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Objectives The goal of this analysis was to determine whether intensive statin therapy, compared with moderate-dose sta-
tin therapy, leads to a reduction in major adverse cardiovascular events (MACE) among patients undergoing per-
cutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).
Background When compared with moderate-dose statins, intensive statin therapy reduces MACE among patients with ACS.
The role of intensive statin therapy specifically among patients who undergo PCI for ACS is unknown.
Methods Outcomes were compared in 2,868 patients who underwent PCI for ACS just prior to enrollment in the PROVE
IT–TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction
22) trial, which randomized patients to either atorvastatin 80 mg or pravastatin 40 mg daily. The incidence of
the primary composite end point of all-cause mortality, myocardial infarction, unstable angina leading to hospi-
talization, and revascularization after 30 days and stroke was evaluated, as was the incidence of target vessel
revascularization (TVR) and non-TVR during follow-up.
Results Treatment with 80mg atorvastatin reduced the incidence of the composite end point (21.5% vs. 26.5%, hazard ratio: 0.78,
95% confidence interval: 0.67 to 0.91, p 0.002) and lowered the incidence of both TVR (11.4% vs. 15.4%, p 0.001)
and non-TVR (8.0% vs. 10.5%, p 0.017) compared with 40mg pravastatin. After adjusting for on-treatment serum low-
density lipoprotein cholesterol and C-reactive protein concentrations, the odds of TVR with high-dose statin therapy re-
mained significant (odds ratio: 0.74, p 0.015) while the odds of non-TVR did not (odds ratio: 0.92, p 0.55).
Conclusions Among patients with ACS who undergo PCI, intensive statin therapy reduces MACE compared with moderate-
dose statin therapy. The reduction in the incidence of TVR was independent of low-density lipoprotein cholesterol
and C-reactive protein lowering and may therefore be due, at least in part, to a pleiotropic effect of high-dose
statin therapy. (PROVE IT–TIMI 22; NCT00382460) (J Am Coll Cardiol 2009;54:2290–5) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.010e
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009, accepted September 14, 2009.vents, including death and myocardial infarction (MI),
ompared with moderate-dose therapy (1–3). While the
reponderance of evidence suggests that a lower serum
oncentration of low-density lipoprotein cholesterol
LDL-C) is associated with improved outcomes (4), the
enefits of therapy with high-dose statins may extend
eyond those directly attributable to their lipid-lowering
ffect (5–7). These nonlipid-lowering benefits have been
ermed pleiotropic effects. The effect of intensive versus
oderate lipid-lowering therapy on cardiovascular out-
omes among patients who have undergone percutaneous
oronary intervention (PCI) for ACS is less well estab-
ished. Furthermore, the effects on target vessel revascu-
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eported.
The PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
valuation and Infection Therapy–Thrombolysis In Myo-
ardial Infarction 22) study enrolled 4,162 ACS patients and
andomized them to either intensive therapy with 80 mg
torvastatin daily or moderate therapy with 40 mg of prava-
tatin daily (1). The goals of this analysis were: 1) to determine
hether patients who underwent PCI for their index event
erived benefit from intensive statin therapy; and 2) to evaluate
hether reductions in TVR and non-TVR remained significant
fter adjusting for on-treatment levels of LDL-C and C-reactive
rotein (CRP).
ethods
atient population. The design and main results of the
ROVE IT–TIMI 22 study have been described (1,8).
riefly, patients at least 18 years old were eligible for
nclusion if they had been hospitalized for ACS, either acute
I (with or without electrocardiographic evidence of ST-
egment elevation) or high-risk unstable angina, in the
receding 10 days. Patients had to be in stable condition
nd were to be enrolled after angiography and PCI, if
eemed warranted by the treating physician. Finally, pa-
ients had to have a total cholesterol level of 240 mg/dl (6.21
mol/l) or less, measured at the local hospital within the
rst 24 h after the onset of the ACS or up to 6 months
arlier if no sample had been obtained during the first 24 h.
atients who were receiving long-term lipid-lowering ther-
py at the time of their index ACS had to have a total
holesterol level of 200 mg/dl (5.18 mmol/l) or less at the
ime of screening in the local hospital. Patients were
nrolled up to 10 days after the index event.
rotocol. Patients were treated with standard medical and
nterventional therapy for ACS, including aspirin, clopi-
ogrel, or warfarin when indicated. Patients were not
ermitted to be treated with any lipid-modifying agent
ther than the study drug. Eligible patients were randomly
ssigned in a 1:1 ratio to receive 40 mg of pravastatin or 80
g of atorvastatin daily in a double-blind fashion.
Patients were seen for follow-up visits and received
ietary counseling at 30 days, 4 months, and every 4 months
hereafter until their final visit. Blood samples for core
aboratory assessment were obtained at randomization, 30
ays, 4, 8, 12, and 16 months, and at the final visit for the
easurement of lipids and other components that were part
f the safety assessment. LDL-C levels were monitored, and
he protocol specified that the dose of pravastatin was to
ncrease to 80 mg in a blinded fashion if the LDL-C level
xceeded 125 mg/dl (3.23 mmol/l) on 2 consecutive visits
nd the patient had been taking study medication.
nd points. The outcome measure in the current analysis
as the time from randomization until the first occurrence
f a component of the primary end point from the PROVE
T–TIMI 22 trial: death from any cause, MI, documented anstable angina requiring rehos-
italization and revascularization
PCI or coronary artery bypass
rafting [CABG]) at least 30
ays after randomization, and
troke. An additional outcome
easure was the rate of TVR and
on-TVR procedures performed
t least 30 days after randomiza-
ion over the period of follow-up
mean 24 months). TVR was
efined as revascularization (ei-
her PCI or CABG) of a vessel
reviously treated by PCI during
he index hospitalization. Non-
VR was defined as revascular-
zation of a vessel that had not
een treated by PCI during the
ndex hospitalization.
tatistical analysis. Continuous variable values are re-
orted as the median and interquartile range, and categor-
cal data are reported as percentages. In the comparison of
aseline characteristics, differences in continuous variables
ere analyzed using the Wilcoxon rank sum test, and
ifferences in categorical variables were analyzed using the
hi-square test. Event rates were calculated using the
aplan-Meier cumulative failure function. Cox propor-
ional hazard models were used for the analysis of clinical
nd points and statin randomization treatment.
Univariate analyses were performed to explore the asso-
iations between the intensity of statin therapy and rates of
VR and non-TVR. Multivariate logistic regression anal-
sis was performed to assess the independent association
etween the intensity of statin therapy and rates of TVR
nd non-TVR, adjusting for the 30-day on-treatment
DL-C and CRP concentrations. A separate model adjust-
ng for the on-treatment improvement (change) in LDL-C
nd CRP was additionally constructed. All analyses were
erformed using Stata version 9.0 (Stata Corp., College
tation, Texas).
esults
aseline characteristics. Of the 4,162 patients enrolled
n the trial, 2,868 (68.9%) underwent PCI for the index
CS prior to randomization. The baseline characteristics
re displayed in Table 1. Patients who underwent PCI for
he treatment of the index event were significantly
ounger; were less likely to have diabetes mellitus, hy-
ertension, or peripheral arterial disease or to have had a
rior MI or CABG; and were more likely to have been
aking a statin at the time of the index event. Patients
ho underwent PCI had a higher median baseline CRP
nd were more likely current smokers. Despite these
ifferences, the baseline characteristics of the 80 mg
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CABG  coronary artery
bypass grafting
CI  confidence interval
CRP  C-reactive protein
HR  hazard ratio
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
TVR  target vessel
revascularizationtorvastatin versus 40 mg pravastatin comparison in
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Aggressive Lipid-Lowering Therapy and Target Vessel Revascularization December 8, 2009:2290–5ither the PCI cohort or the non-PCI cohort were not
tatistically significant with the exception of a history of
eripheral arterial disease, which was more common
mong patients who underwent PCI and were random-
zed to 40 mg pravastatin.
ffect of treatment allocation in PCI and non-PCI
roups. At the time of randomization, the median serum
DL-C concentration was 106 mg/dl in both groups. The
edian LDL-C concentration at 30 days was 89 mg/dl in
he 40 mg pravastatin/PCI group (n  1,425) and 56.5
g/dl in the 80 mg atorvastatin/PCI group (n  1,442)
p  0.001). Similarly, the achieved median LDL-C levels
t 30 days were 87 mg/dl in the 40 mg pravastatin/no PCI
roup (n  637) and 58 mg/dl in the 80 mg atorvastatin/no
CI group (n  657) (p  0.001) (Table 2).
The median serum CRP concentration was 13.2 mg/l in
he PCI group and 9.4 mg/l in the no PCI group. The CRP
oncentration at 30 days was 2.14 mg/l in the 40 mg
ravastatin/PCI group, 1.55 mg/l in the 80 mg atorvastatin/
aseline Characteristics of Patients by PCI for Index Event and TreTable 1 Baseline Characteristics of Patients by PCI for Index E
PCI/Atorvastatin
(n  1,442)
PCI/Pravastatin
(n  1,425)
Age, yrs 57.1  10.5 57.0  10.9
Male sex 1,144 (79.3) 1,127 (79.1)
White race 1,318 (91.4) 1,297 (91.1)
Diabetes mellitus 220 (15.3) 234 (16.4)
Hypertension 704 (48.8) 672 (47.2)
Current smoker 546 (37.9) 553 (38.8)
Prior MI 205 (14.2) 220 (15.4)
Prior PCI 204 (14.2) 216 (15.2)
Prior CABG 99 (6.9) 111 (7.8)
PAD* 52 (3.6) 75 (5.3)
Prior statin therapy 316 (21.9) 313 (22.0)
Index event
UA 352 (24.4) 350 (24.6)
NSTEMI 515 (35.7) 550 (38.6)
STEMI 575 (39.9) 525 (36.8)
Lipids and CRP
Total cholesterol
Number of patients 1,385 1,372
Median, mg/dl 181 (160–204) 181 (159–203)
LDL-C
Number of patients 1,381 1,374
Median, mg/dl 107 (89–128) 106 (88–127)
HDL-C
Number of patients 1,385 1,372
Median, mg/dl 38 (32–45) 38 (32–44.5)
Triglycerides
Number of patients 1,387 1,375
Median, mg/dl 157 (120–213) 156 (117–210)
CRP
Number of patients 1,369 1,359
Median, mg/l 13.5 (5.3–31.1) 13.0 (5.9–29.8)
alues are presented as mean  SD, n (%), or median (interquartile range). *Indicates significanc
CABG  coronary artery bypass graft surgery; CRP  C-reactive protein; HDL-C  high-density lip
on–ST-segment elevation myocardial infarction; PAD peripheral arterial disease; PCI percutaCI group (p  0.001), 2.63 mg/l in the 40 mg pravasta- sin/no PCI group, and 1.88 mg/l in the 80 mg atorvasta-
in/no PCI group (p  0.001).
linical outcomes. Among patients who underwent PCI
or the index event, the 2-year Kaplan-Meier estimated
vent rate for the primary composite end point (death from
ny cause, MI, documented unstable angina requiring re-
ospitalization and revascularization [PCI or CABG] at
east 30 days after randomization, and stroke) was 21.5%
mong patients receiving 80 mg atorvastatin and 26.5%
mong those receiving 40 mg pravastatin, representing a
2% relative risk reduction in the hazard ratio (HR)
avoring atorvastatin (HR: 0.78, 95% confidence interval
CI]: 0.67 to 0.91, p  0.001) (Fig. 1A, Table 3). The
omposite of cardiovascular death, nonfatal MI, recurrent
schemia, and rehospitalization for unstable angina was
eached by 15.4% of patients randomized to 80 mg atorva-
tatin and 20.1% of those randomized to 40 mg pravastatin
HR: 0.73, 95% CI: 0.61 to 0.87, p  0.001) (Fig. 1B).
In the PCI cohort, there were significant reductions in
ntand Treatment
No PCI/Atorvastatin
(n  652)
No PCI/Pravastatin
(n  633)
p Value for
PCI vs. No PCI
60.2  12.1 61.4  11.4 0.001
486 (75.5) 485 (76.6) 0.009
588 (90.2) 563 (88.9) 0.086
153 (23.5) 124 (19.6) 0.001
371 (56.9) 340 (53.7) 0.001
217 (33.3) 213 (33.7) 0.003
167 (25.6) 173 (27.3) 0.001
118 (18.1) 104 (16.4) 0.030
134 (20.6) 109 (17.2) 0.001
52 (8.0) 60 (9.5) 0.001
217 (33.3) 198 (31.3) 0.001
0.001
251 (38.5) 261 (41.4)
231 (35.4) 205 (32.5)
170 (26.1) 165 (26.2)
0.582
625 604
180 (160–206) 178 (157–202)
0.154
618 595
105 (88–126) 105 (86–126)
0.001
625 604
39 (33–47) 39 (34–47)
0.068
625 604
159 (118–214) 150 (113–203)
0.001
608 588
9.4 (3.8–23.8) 9.4 (3.7–28.3)
e 0.05 level in the PCI cohort.
in cholesterol; LDL-C  low-density lipoprotein cholesterol; MI myocardial infarction; NSTEMI 
oronary intervention; STEMI ST-segment elevation myocardial infarction; UA unstable angina.atmevent
e at theveral of the individual components of the primary and
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ncluding recurrent ischemia (13.0% vs. 17.1%, HR: 0.71,
5% CI: 0.58 to 0.86, p  0.001), rehospitalization for
nstable angina (3.3% vs. 4.7%, HR: 0.65, 95% CI: 0.45 to
.96, p  0.029), revascularization 30 days after random-
zation (16.6% vs. 21.0%, HR: 0.76, 95% CI: 0.64 to 0.90,
 0.002), the composite of death and MI (7.1% vs. 9.9%,
R: 0.71, 95% CI: 0.55 to 0.92, p  0.009), and strong
rends favoring atorvastatin in all-cause mortality alone
1.5% vs. 2.5%, HR: 0.62, 95% CI: 0.37 to 1.02, p 0.057)
nd MI alone (5.8% vs. 7.7%, HR: 0.75, 95% CI: 0.56 to
ffect of Statin Therapy on Lipids and CRPTable 2 Effect of Statin Therapy on Lipids and CRP
Statin Regimen Baseline 30 Days
Patients with PCI for index event
Total cholesterol, mg/dl (median)
Pravastatin, 40 mg 181 162
Atorvastatin, 80 mg 181 120
p value 0.460 0.001
LDL-C, mg/dl (median)
Pravastatin, 40 mg 106 89
Atorvastatin, 80 mg 107 56.5
p value 0.700 0.001
HDL-C, mg/dl (median)
Pravastatin, 40 mg 38 40
Atorvastatin, 80 mg 38 38
p value 0.687 0.001
Triglycerides, mg/dl (median)
Pravastatin, 40 mg 156 143
Atorvastatin, 80 mg 157 109.5
p value 0.243 0.001
CRP, mg/l (median)
Pravastatin, 40 mg 13.0 2.14
Atorvastatin, 80 mg 13.5 1.55
p value 0.931 0.001
Patients without PCI for index event
Total cholesterol, mg/dl (median)
Pravastatin, 40 mg 178 159
Atorvastatin, 80 mg 180 121
p value 0.213 0.001
LDL-C, mg/dl (median)
Pravastatin, 40 mg 105 87
Atorvastatin, 80 mg 105 58
p value 0.564 0.001
HDL-C, mg/dl (median)
Pravastatin, 40 mg 39 42
Atorvastatin, 80 mg 39 39
p value 0.354 0.001
Triglycerides, mg/dl (median)
Pravastatin, 40 mg 150 126
Atorvastatin, 80 mg 159 106.2
p value 0.102 0.001
CRP, mg/l (median)
Pravastatin, 40 mg 9.45 2.63
Atorvastatin, 80 mg 9.37 1.88
p value 0.364 0.001
bbreviations as in Table 1..00, p  0.052). There was no significant differenceetween 80 mg atorvastatin and 40 mg pravastatin in terms
f the incidence of stroke among patients treated with PCI
uring the index hospitalization.
Among patients who were medically managed for the
ndex event, comprising less than one-third of the full trial
opulation, there were no significant differences between
atients randomized to 80 mg atorvastatin or 40 mg
ravastatin in terms of the primary end point (24.5% vs.
5.2%, HR: 0.97, 95% CI: 0.78 to 1.21, p  0.779) and
econdary end point (16.5% vs. 19.2%, HR: 0.84, 95% CI:
.65 to 1.09, p  0.183). However, neither of the interac-
ion p values were significant evaluating the difference
etween the benefit of intensive- compared with moderate-
ose statin therapy as a function of treatment strategy (PCI
s. no PCI) (p  0.119 for interaction for primary end
oint). The interaction p value for the secondary end point
as 0.124.
ffect of treatment allocation on TVR versus non-TVR.
igh-dose statin therapy compared with moderate-dose
herapy reduced the incidence of both TVR (11.4% vs.
5.4%, odds ratio [OR]: 0.73, 95% CI: 0.59 to 0.89, p 
.001) and non-TVR (8.0% vs. 10.5%, OR: 0.75, 95% CI:
.59 to 0.95, p  0.017) (Fig. 2). After adjusting for 30-day
n-treatment serum LDL-C and CRP concentration, in-
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Figure 1 Primary and Secondary End Points
Kaplan-Meier estimates of the incidence of the primary end point (A) and the
composite of death, myocardial infarction (MI), recurrent ischemia (RI), and
unstable angina (UA) requiring rehospitalization (B) among patients who under-
went percutaneous coronary intervention for the index event. CI  confidence
interval.
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Aggressive Lipid-Lowering Therapy and Target Vessel Revascularization December 8, 2009:2290–5ensive statin therapy remained associated with a reduction
n the rate of TVR (OR: 0.74, 95% CI: 0.59 to 0.95, p 
.015), but was not significantly associated with a reduction
n the rate of non-TVR (OR: 0.92, 95% CI: 0.70 to 1.21,
 0.55). Adjustment for the on-treatment improvement
n LDL-C and CRP in the model yielded similar results.
iscussion
n this post-hoc subgroup analysis of the PROVE IT–
IMI 22 study, patients who underwent PCI for ACS and
ere randomized to high-dose atorvastatin had a significant
eduction in adverse cardiovascular events compared with
CI patients randomized to moderate-dose pravastatin.
dditionally, after adjusting for mean on-treatment
DL-C and CRP concentrations, there was no significant
ifference between intensive and moderate therapy in non-
VR, but there remained a significant difference in TVR,
uggesting that the reduction in TVR might be mediated, at
east in part, by a pleiotropic mechanism of high-dose
torvastatin not accounted for by reductions in LDL-C or
arkers of systemic inflammation.
utcomes by Statin Therapy Among Patients With PCI for Index EvTable 3 Outcomes by Statin Therapy Among Patients With PCI
End Point for Patients With PCI for
Index Event
Hazard Ratio
(95% CI)
Primary end point 0.78 (0.67–0.91)
Death/MI/RI/UA with rehospitalization 0.73 (0.61–0.87)
Death 0.62 (0.37–1.02)
MI 0.75 (0.56–1.00)
Stroke 1.24 (0.49–3.14)
Recurrent ischemia 0.71 (0.58–0.86)
UA with rehospitalization 0.65 (0.45–0.96)
Revascularization after 30 days 0.76 (0.64–0.90)
I  confidence interval; RI  recurrent ischemia; other abbreviations as in Table 1.
Univariate OR 0.73, p<0.001
M lti i t OR 0 74 0 015
15.4%
16%
20%
u var a e  . , p= .
Univariate OR 0.75, p=0.017
Multivariate OR 0.92, p=0.55
11.4%
8.0%
10.5%
8%
12%
0%
4%
RVT-noNRVT
Atorvastatin Pravastatin
Figure 2 TVR Versus Non-TVR
Incidence of target vessel revascularization (TVR) and non-TVR among patients
who underwent percutaneous coronary intervention for the index event strati-
fied by treatment allocation. Multivariate odds ratio (OR) adjusted for on-treatment
low-density lipoprotein cholesterol and C-reactive protein concentrations.cThere was no significant interaction between the benefit
f intensive- compared with moderate-dose statin therapy
s a function of PCI, although, as previously reported (9), in
he subgroup of patients who were medically managed
comprising less than one-third of the trial), there was not
statistically significant reduction in adverse cardiovascular
vents with high-dose atorvastatin.
This is the first report of intensive versus moderate statin
herapy in PCI patients. Prior studies have demonstrated
he benefit of standard-dose statin therapy over placebo in
CI patients (10), and the results presented here demon-
trate an additional 22% relative decrease in major adverse
ardiac events associated with intensive therapy over mod-
rate lipid-lowering therapy. These data, coupled with those
rom studies enrolling patients with stable coronary disease
ho have undergone PCI (11), strongly suggest that pa-
ients who undergo PCI should be treated with intensive
tatin therapy. Indeed, the most recent PCI guidelines
ecommend that patients undergoing PCI should be started
n a statin before discharge and that it is reasonable to target
n LDL-C 70 mg/dl (12).
The mechanism underlying the difference in benefit
etween patients who underwent PCI and those who were
edically managed is unknown. Patients who underwent
CI had a significant reduction in TVR, a possible surro-
ate for in-stent restenosis. That patients who were medi-
ally managed could not benefit in this regard may account
or at least part of the difference in clinical outcomes.
The clinical benefit of statins in secondary prevention is
erived, at least in part, from their LDL-C–lowering effect
4). However, there is increasing evidence that the benefits
f statin therapy in patients with ACS may also be due to
on–LDL-C–lowering effects referred to as pleiotropic
echanisms (5–7,13). Pleiotropic effects have been specu-
ated to include benefits in the reduction of inflammation,
laque stability, and endothelial function, and the magni-
ude and timing of reductions in cardiovascular events seen
n some clinical trials may not be explained solely by
DL-C lowering (1,14).
The modest effects of statins on coronary artery luminal
iameter determined angiographically in prior trials (15–19)
ndex Event
2-Yr Event Rates (%)
Log-Rank
p ValueAtorvastatin Pravastatin
21.5 26.5 0.001
15.4 20.1 0.001
1.5 2.5 0.057
5.8 7.7 0.052
0.66 0.62 0.648
13.0 17.1 0.001
3.3 4.7 0.029
16.6 21.0 0.002entfor Iompared with the dramatic reductions in clinical coronary
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December 8, 2009:2290–5 Aggressive Lipid-Lowering Therapy and Target Vessel Revascularizationvents seen in clinical trials suggests a possible role of
ipid-lowering agents in plaque stabilization in addition to
heir role in reversing atherosclerosis. Reductions in circu-
ating LDL-C levels may play a role in altering plaque
tructure and plaque biology (20). However, some of the
ffects of statins on plaque stability appear to be indepen-
ent of LDL-C lowering (21). For instance, statins inhibit
eranylgeranylation and farnesylation of the GTP binding
roteins Rho and Ras, which clearly play a role in the
rogression of atherosclerosis (22,23). Whether these pleio-
ropic effects are clinically relevant remains to be definitively
roven, although the results presented here are provocative
n that regard.
tudy limitations. Strict enrollment criteria are used in
linical trials, and the results observed here may not be
pplicable to all patients in clinical practice. While we
nalyzed the association of intensive and standard lipid-
owering therapy with TVR, the association with target
esion revascularization was not evaluated. Detailed angio-
raphic findings were not collected. The present study was
onducted in the era of bare-metal stents, and the applica-
ility of these results to patients treated with drug-eluting
tents is not known. Patients who achieved similar LDL-C
nd CRP in the 2 treatment arms may have very different
aseline characteristics, and comparing the 2 treatment arms
fter adjusting for LDL-C and CRP is not a randomized
omparison. Though the OR for non-TVR is not signifi-
ant after adjusting for LDL-C and CRP, the 95% CIs for
VR and non-TVR overlap with that for the reduction in
he primary composite outcome.
onclusions
mong patients treated with PCI in the PROVE IT–TIMI
2 study, high-dose statin therapy reduced TVR and non-
VR as well as the primary composite end point. The
enefits in non-TVR, but not TVR, appear to be explained
y reductions in on-treatment LDL-C and CRP, suggest-
ng a possible pleiotropic mechanism of high-dose statin
herapy.
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